The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review
Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious de...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Owczarczyk-Saczonek, Agnieszka [verfasserIn] Kasprowicz-Furmańczyk, Marta [verfasserIn] Kruszewska, Anna [verfasserIn] Krajewska-Włodarczyk, Magdalena [verfasserIn] Bechtold, Agata [verfasserIn] Klimek, Paulina [verfasserIn] Placek, Waldemar [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Dermatology and therapy - Heidelberg : Springer, 2011, 10(2020), 6 vom: 02. Sept., Seite 1423-1434 |
|---|---|
| Übergeordnetes Werk: |
volume:10 ; year:2020 ; number:6 ; day:02 ; month:09 ; pages:1423-1434 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13555-020-00438-z |
|---|
| Katalog-ID: |
SPR041842464 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR041842464 | ||
| 003 | DE-627 | ||
| 005 | 20230519182453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201109s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13555-020-00438-z |2 doi | |
| 035 | |a (DE-627)SPR041842464 | ||
| 035 | |a (SPR)s13555-020-00438-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Owczarczyk-Saczonek, Agnieszka |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. | ||
| 650 | 4 | |a Correction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a FAL |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fractional ablative laser |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hyaluronic acid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Morphea |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Scleroderma |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kasprowicz-Furmańczyk, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Kruszewska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Krajewska-Włodarczyk, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Bechtold, Agata |e verfasserin |4 aut | |
| 700 | 1 | |a Klimek, Paulina |e verfasserin |4 aut | |
| 700 | 1 | |a Placek, Waldemar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatology and therapy |d Heidelberg : Springer, 2011 |g 10(2020), 6 vom: 02. Sept., Seite 1423-1434 |w (DE-627)723900000 |w (DE-600)2680284-3 |x 2190-9172 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:6 |g day:02 |g month:09 |g pages:1423-1434 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13555-020-00438-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 6 |b 02 |c 09 |h 1423-1434 | ||
| author_variant |
a o s aos m k f mkf a k ak m k w mkw a b ab p k pk w p wp |
|---|---|
| matchkey_str |
article:21909172:2020----::hcretoofcamrhaeinbhauoiaiaaeei |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.1007/s13555-020-00438-z doi (DE-627)SPR041842464 (SPR)s13555-020-00438-z-e DE-627 ger DE-627 rakwb eng 610 ASE Owczarczyk-Saczonek, Agnieszka verfasserin aut The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. Correction (dpeaa)DE-He213 FAL (dpeaa)DE-He213 Fractional ablative laser (dpeaa)DE-He213 Hyaluronic acid (dpeaa)DE-He213 Morphea (dpeaa)DE-He213 Scleroderma (dpeaa)DE-He213 Kasprowicz-Furmańczyk, Marta verfasserin aut Kruszewska, Anna verfasserin aut Krajewska-Włodarczyk, Magdalena verfasserin aut Bechtold, Agata verfasserin aut Klimek, Paulina verfasserin aut Placek, Waldemar verfasserin aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 10(2020), 6 vom: 02. Sept., Seite 1423-1434 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:10 year:2020 number:6 day:02 month:09 pages:1423-1434 https://dx.doi.org/10.1007/s13555-020-00438-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2020 6 02 09 1423-1434 |
| spelling |
10.1007/s13555-020-00438-z doi (DE-627)SPR041842464 (SPR)s13555-020-00438-z-e DE-627 ger DE-627 rakwb eng 610 ASE Owczarczyk-Saczonek, Agnieszka verfasserin aut The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. Correction (dpeaa)DE-He213 FAL (dpeaa)DE-He213 Fractional ablative laser (dpeaa)DE-He213 Hyaluronic acid (dpeaa)DE-He213 Morphea (dpeaa)DE-He213 Scleroderma (dpeaa)DE-He213 Kasprowicz-Furmańczyk, Marta verfasserin aut Kruszewska, Anna verfasserin aut Krajewska-Włodarczyk, Magdalena verfasserin aut Bechtold, Agata verfasserin aut Klimek, Paulina verfasserin aut Placek, Waldemar verfasserin aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 10(2020), 6 vom: 02. Sept., Seite 1423-1434 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:10 year:2020 number:6 day:02 month:09 pages:1423-1434 https://dx.doi.org/10.1007/s13555-020-00438-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2020 6 02 09 1423-1434 |
| allfields_unstemmed |
10.1007/s13555-020-00438-z doi (DE-627)SPR041842464 (SPR)s13555-020-00438-z-e DE-627 ger DE-627 rakwb eng 610 ASE Owczarczyk-Saczonek, Agnieszka verfasserin aut The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. Correction (dpeaa)DE-He213 FAL (dpeaa)DE-He213 Fractional ablative laser (dpeaa)DE-He213 Hyaluronic acid (dpeaa)DE-He213 Morphea (dpeaa)DE-He213 Scleroderma (dpeaa)DE-He213 Kasprowicz-Furmańczyk, Marta verfasserin aut Kruszewska, Anna verfasserin aut Krajewska-Włodarczyk, Magdalena verfasserin aut Bechtold, Agata verfasserin aut Klimek, Paulina verfasserin aut Placek, Waldemar verfasserin aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 10(2020), 6 vom: 02. Sept., Seite 1423-1434 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:10 year:2020 number:6 day:02 month:09 pages:1423-1434 https://dx.doi.org/10.1007/s13555-020-00438-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2020 6 02 09 1423-1434 |
| allfieldsGer |
10.1007/s13555-020-00438-z doi (DE-627)SPR041842464 (SPR)s13555-020-00438-z-e DE-627 ger DE-627 rakwb eng 610 ASE Owczarczyk-Saczonek, Agnieszka verfasserin aut The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. Correction (dpeaa)DE-He213 FAL (dpeaa)DE-He213 Fractional ablative laser (dpeaa)DE-He213 Hyaluronic acid (dpeaa)DE-He213 Morphea (dpeaa)DE-He213 Scleroderma (dpeaa)DE-He213 Kasprowicz-Furmańczyk, Marta verfasserin aut Kruszewska, Anna verfasserin aut Krajewska-Włodarczyk, Magdalena verfasserin aut Bechtold, Agata verfasserin aut Klimek, Paulina verfasserin aut Placek, Waldemar verfasserin aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 10(2020), 6 vom: 02. Sept., Seite 1423-1434 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:10 year:2020 number:6 day:02 month:09 pages:1423-1434 https://dx.doi.org/10.1007/s13555-020-00438-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2020 6 02 09 1423-1434 |
| allfieldsSound |
10.1007/s13555-020-00438-z doi (DE-627)SPR041842464 (SPR)s13555-020-00438-z-e DE-627 ger DE-627 rakwb eng 610 ASE Owczarczyk-Saczonek, Agnieszka verfasserin aut The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. Correction (dpeaa)DE-He213 FAL (dpeaa)DE-He213 Fractional ablative laser (dpeaa)DE-He213 Hyaluronic acid (dpeaa)DE-He213 Morphea (dpeaa)DE-He213 Scleroderma (dpeaa)DE-He213 Kasprowicz-Furmańczyk, Marta verfasserin aut Kruszewska, Anna verfasserin aut Krajewska-Włodarczyk, Magdalena verfasserin aut Bechtold, Agata verfasserin aut Klimek, Paulina verfasserin aut Placek, Waldemar verfasserin aut Enthalten in Dermatology and therapy Heidelberg : Springer, 2011 10(2020), 6 vom: 02. Sept., Seite 1423-1434 (DE-627)723900000 (DE-600)2680284-3 2190-9172 nnns volume:10 year:2020 number:6 day:02 month:09 pages:1423-1434 https://dx.doi.org/10.1007/s13555-020-00438-z kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2020 6 02 09 1423-1434 |
| language |
English |
| source |
Enthalten in Dermatology and therapy 10(2020), 6 vom: 02. Sept., Seite 1423-1434 volume:10 year:2020 number:6 day:02 month:09 pages:1423-1434 |
| sourceStr |
Enthalten in Dermatology and therapy 10(2020), 6 vom: 02. Sept., Seite 1423-1434 volume:10 year:2020 number:6 day:02 month:09 pages:1423-1434 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Correction FAL Fractional ablative laser Hyaluronic acid Morphea Scleroderma |
| dewey-raw |
610 |
| isfreeaccess_bool |
true |
| container_title |
Dermatology and therapy |
| authorswithroles_txt_mv |
Owczarczyk-Saczonek, Agnieszka @@aut@@ Kasprowicz-Furmańczyk, Marta @@aut@@ Kruszewska, Anna @@aut@@ Krajewska-Włodarczyk, Magdalena @@aut@@ Bechtold, Agata @@aut@@ Klimek, Paulina @@aut@@ Placek, Waldemar @@aut@@ |
| publishDateDaySort_date |
2020-09-02T00:00:00Z |
| hierarchy_top_id |
723900000 |
| dewey-sort |
3610 |
| id |
SPR041842464 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR041842464</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519182453.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201109s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13555-020-00438-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR041842464</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13555-020-00438-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Owczarczyk-Saczonek, Agnieszka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Correction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">FAL</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fractional ablative laser</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hyaluronic acid</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Morphea</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Scleroderma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kasprowicz-Furmańczyk, Marta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kruszewska, Anna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krajewska-Włodarczyk, Magdalena</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bechtold, Agata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klimek, Paulina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Placek, Waldemar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Dermatology and therapy</subfield><subfield code="d">Heidelberg : Springer, 2011</subfield><subfield code="g">10(2020), 6 vom: 02. Sept., Seite 1423-1434</subfield><subfield code="w">(DE-627)723900000</subfield><subfield code="w">(DE-600)2680284-3</subfield><subfield code="x">2190-9172</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield><subfield code="g">day:02</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:1423-1434</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13555-020-00438-z</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield><subfield code="b">02</subfield><subfield code="c">09</subfield><subfield code="h">1423-1434</subfield></datafield></record></collection>
|
| author |
Owczarczyk-Saczonek, Agnieszka |
| spellingShingle |
Owczarczyk-Saczonek, Agnieszka ddc 610 misc Correction misc FAL misc Fractional ablative laser misc Hyaluronic acid misc Morphea misc Scleroderma The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review |
| authorStr |
Owczarczyk-Saczonek, Agnieszka |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)723900000 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2190-9172 |
| topic_title |
610 ASE The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review Correction (dpeaa)DE-He213 FAL (dpeaa)DE-He213 Fractional ablative laser (dpeaa)DE-He213 Hyaluronic acid (dpeaa)DE-He213 Morphea (dpeaa)DE-He213 Scleroderma (dpeaa)DE-He213 |
| topic |
ddc 610 misc Correction misc FAL misc Fractional ablative laser misc Hyaluronic acid misc Morphea misc Scleroderma |
| topic_unstemmed |
ddc 610 misc Correction misc FAL misc Fractional ablative laser misc Hyaluronic acid misc Morphea misc Scleroderma |
| topic_browse |
ddc 610 misc Correction misc FAL misc Fractional ablative laser misc Hyaluronic acid misc Morphea misc Scleroderma |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Dermatology and therapy |
| hierarchy_parent_id |
723900000 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Dermatology and therapy |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)723900000 (DE-600)2680284-3 |
| title |
The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review |
| ctrlnum |
(DE-627)SPR041842464 (SPR)s13555-020-00438-z-e |
| title_full |
The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review |
| author_sort |
Owczarczyk-Saczonek, Agnieszka |
| journal |
Dermatology and therapy |
| journalStr |
Dermatology and therapy |
| lang_code |
eng |
| isOA_bool |
true |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
1423 |
| author_browse |
Owczarczyk-Saczonek, Agnieszka Kasprowicz-Furmańczyk, Marta Kruszewska, Anna Krajewska-Włodarczyk, Magdalena Bechtold, Agata Klimek, Paulina Placek, Waldemar |
| container_volume |
10 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Owczarczyk-Saczonek, Agnieszka |
| doi_str_mv |
10.1007/s13555-020-00438-z |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
correction of facial morphea lesions by hyaluronic acid: a case series and literature review |
| title_auth |
The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review |
| abstract |
Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. |
| abstractGer |
Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. |
| abstract_unstemmed |
Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
6 |
| title_short |
The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review |
| url |
https://dx.doi.org/10.1007/s13555-020-00438-z |
| remote_bool |
true |
| author2 |
Kasprowicz-Furmańczyk, Marta Kruszewska, Anna Krajewska-Włodarczyk, Magdalena Bechtold, Agata Klimek, Paulina Placek, Waldemar |
| author2Str |
Kasprowicz-Furmańczyk, Marta Kruszewska, Anna Krajewska-Włodarczyk, Magdalena Bechtold, Agata Klimek, Paulina Placek, Waldemar |
| ppnlink |
723900000 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13555-020-00438-z |
| up_date |
2024-07-03T23:51:27.622Z |
| _version_ |
1803603869824974850 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR041842464</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519182453.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201109s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13555-020-00438-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR041842464</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13555-020-00438-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Owczarczyk-Saczonek, Agnieszka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Correction of Facial Morphea Lesions by Hyaluronic Acid: A Case Series and Literature Review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction The aim of the study is to assess the long-term safety and efficacy of hyaluronic acid (HA) administration in correction of facial morphea lesions and to review the literature on the subject. Morphea is a chronic inflammatory disease of the connective tissue which may lead to serious deformations. The lesions located on the face particularly affect patients’ quality of life and self-esteem; thus, there is a demand for safe and effective methods of treatment. Case Presentation The paper presents three female patients aged 16, 17 and 70 with facial morphea lesions who had HA preparation $ Juvéderm^{®} $ Voluma or Volux, $ Vycross^{®} $ technology, Allergan, injected. One of the patients had additionally fractional ablative $ CO_{2} $ laser (FAL) therapy. Discussion The literature provides reports on successful use of HA, polymethylmethacrylate and poly-l-lactic acid for the correction of facial defects in localized scleroderma. HA is a natural component of the extracellular matrix and it therefore minimizes the probability of immunogenicity. The application technique also plays an important role. On the other hand, FAL therapy leads to the degradation of the abnormal collagen and the induction of normal collagen synthesis. Conclusions HA injection and combination of HA application with FAL are minimally invasive, effective and safe therapeutic options for patients suffering from morphea.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Correction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">FAL</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fractional ablative laser</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hyaluronic acid</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Morphea</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Scleroderma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kasprowicz-Furmańczyk, Marta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kruszewska, Anna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krajewska-Włodarczyk, Magdalena</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bechtold, Agata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klimek, Paulina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Placek, Waldemar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Dermatology and therapy</subfield><subfield code="d">Heidelberg : Springer, 2011</subfield><subfield code="g">10(2020), 6 vom: 02. Sept., Seite 1423-1434</subfield><subfield code="w">(DE-627)723900000</subfield><subfield code="w">(DE-600)2680284-3</subfield><subfield code="x">2190-9172</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield><subfield code="g">day:02</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:1423-1434</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13555-020-00438-z</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield><subfield code="b">02</subfield><subfield code="c">09</subfield><subfield code="h">1423-1434</subfield></datafield></record></collection>
|
| score |
7.4008226 |